Understanding an experimental peptide-derived compound, dihexa, its proposed effects on brain connectivity and memory, and why scientific curiosity must be accompanied by appropriate caution.
Curator’s Note: The essay written by Dr Mehmet Yildiz as a follow-up chapter of his book titled Neuropeptides for Cognition, Healthspan and Graceful Aging discusses the compound Dihexa peptide, emphasizing its potential role in enhancing brain connectivity and memory. Derived from angiotensin IV, Dihexa is sometimes described as extraordinarily potent, with claims that it is 10 million times stronger than BDNF. However, the author stresses the need to interpret extraordinary claims cautiously, noting that current evidence comes primarily from animal studies, which may not translate to human efficacy or safety. Dihexa has not undergone human clinical trials and lacks FDA approval. Ultimately, the discussion reflects the need for scientific curiosity coupled with a measured approach, acknowledging both existing evidence and the limitations of current findings. You can read his relevant chapter on Medium titled Dihexa and the Science of Synaptic Expansion.
Why I Decided to Write This Essay
Imagine hearing about a molecule that could help your brain develop new connections and potentially improve memory. Now imagine someone telling you that this molecule is 10 million times more powerful than BDNF, one of the most important proteins involved in neuronal survival and synaptic plasticity. It sounds extraordinary, especially for people concerned about cognitive decline, Alzheimer’s disease, or maintaining mental sharpness as they age.
This is the kind of attention Dihexa has attracted in some online discussions about neuroscience, longevity, and cognitive enhancement. Some descriptions portray it almost as a miracle molecule capable of dramatically improving neural connectivity. I understand the excitement because the underlying scientific questions are fascinating. However, extraordinary biological claims require careful interpretation, especially when laboratory findings are presented as evidence of benefits in humans.
After my recent chapter on synaptogenesis, several readers and colleagues asked about Dihexa and why my scientific assessment was more cautious than some enthusiastic online articles. As a cognitive scientist, I welcome these questions because they let me explain the difference between promising experimental findings and established clinical evidence. In this essay, I will summarize what Dihexa is, why researchers became interested in it, what the available evidence indicates, and what remains unknown.
What Exactly Is Dihexa?
Dihexa is a synthetic compound developed from research involving angiotensin IV, a peptide derived from the body’s renin–angiotensin system. Although it is often described as a peptide, it is more precisely classified as a peptidomimetic. This means scientists chemically designed it to reproduce selected properties of a peptide while modifying its molecular structure to improve characteristics such as metabolic stability.
The compound emerged from research exploring ways to influence biological pathways associated with learning and memory. Earlier angiotensin IV-related molecules attracted attention because experimental studies suggested effects on certain cognitive functions. However, enzymes can rapidly degrade naturally occurring peptides, limiting their usefulness as potential medicines. Researchers therefore investigated modified compounds that might remain biologically active for longer periods.
Dihexa became interesting because early laboratory and animal studies reported effects associated with memory performance and synaptic development. These observations generated hypotheses about its potential influence on neural plasticity. Nevertheless, the original experimental findings have important reliability limitations, and the compound’s biological behavior in humans remains largely unknown.
Why Do Synaptic Connections Matter?
To understand the interest in Dihexa, we first need to understand synaptogenesis. This biological process allows neurons to establish new synaptic connections. These specialized junctions let nerve cells communicate, exchange information, and participate in the neural networks that support learning, memory, and behavior.
When we learn a language, recognize a familiar face, or acquire a new professional skill, our brains change how neurons communicate. Some connections strengthen, others weaken, and certain neural structures remodel. New synaptic contacts may also develop. These changes contribute to neuroplasticity, the brain’s capacity to adapt in response to experience.
However, more connections do not automatically mean better cognition. A healthy brain also needs to refine its networks through selective weakening and pruning. We can think of this process as improving a communication system: adding more connections may increase possibilities, but performance depends on how effectively information moves through the network.
This distinction matters when evaluating compounds linked to synaptic expansion. The key question is not simply how many connections form, but how those connections support meaningful cognitive functions.
How Might Dihexa Influence Brain Connectivity?
One proposed mechanism involves hepatocyte growth factor (HGF) and its receptor, MET. HGF is a signaling protein involved in cellular growth, survival, migration, and tissue repair. When HGF activates the MET receptor, it can trigger intracellular processes linked to cellular adaptation and development.
These signaling pathways have attracted neuroscience interest because neuronal development and synaptic organization depend on coordinated molecular activity. Early Dihexa researchers proposed that the compound might interact with HGF and facilitate MET-related signaling, potentially influencing synaptic formation and memory-related processes.
However, we must distinguish the established biology of HGF/MET signaling from the specific proposed mechanism of Dihexa. The general signaling system is well studied, but a major publication supporting Dihexa’s proposed interaction with this pathway was retracted in 2025. Consequently, the compound’s precise mechanism cannot currently be presented as independently confirmed.
This uncertainty does not eliminate the scientific value of studying growth-factor pathways. It means that researchers need reliable experiments to determine Dihexa’s molecular targets, biological effects, and functional consequences before drawing confident conclusions.
Is Dihexa Really 10 Million Times More Powerful Than BDNF?
This is perhaps the most memorable claim associated with Dihexa. The comparison appeared in an early university research announcement describing experimental findings involving neuronal connections. It has subsequently been repeated in articles and discussions about cognitive enhancement.
BDNF, or brain-derived neurotrophic factor, is a protein involved in neuronal survival, synaptic plasticity, and several mechanisms associated with learning and memory. It participates in complex biological signaling rather than acting as a simple switch for producing new synapses. Its effects depend on receptor activity, brain region, developmental conditions, and interactions with other molecular systems.
The extraordinary Dihexa comparison concerns reported molecular potency in a laboratory setting. Potency describes the concentration required to produce a specified biological response. It does not necessarily describe the maximum benefit a compound can produce, its safety, or its effectiveness in improving human cognition.
For example, a compound might produce a measurable response at a very low concentration in cultured neurons. This would not establish that it improves memory, protects against dementia, or increases intelligence in a living person. Such conclusions require additional experiments involving functional neural activity, behavioral outcomes, appropriate controls, and eventually human clinical studies.
I could not establish that the precise 10-million-fold comparison has been independently reproduced in a reliable, published head-to-head experiment. Given the research-integrity concerns affecting foundational Dihexa studies, I would not treat this numerical claim as an established scientific fact.
The more meaningful question is not how powerful a molecule appears in one laboratory measurement. It is what that activity accomplishes within a living brain and if the effects are beneficial, reproducible, and safe.
What Have Experimental Studies Actually Shown?
Researchers have investigated Dihexa primarily through preclinical research using laboratory systems and animal models. Early publications reported effects on neuronal structures and selected memory-related behaviors. These findings fueled interest in whether modified angiotensin IV compounds might influence biological processes associated with cognition.
Subsequent animal research has also examined Dihexa in experimental models of neurological impairment. For example, a study using an Alzheimer’s-related mouse model reported treatment-associated changes in behavioral performance, synaptic markers, and cellular signaling. Such findings can help generate hypotheses about possible mechanisms, but they do not establish therapeutic benefits in people.
Animal models provide valuable scientific information because researchers can examine molecular and cellular processes that are difficult to study directly in humans. However, laboratory animals do not fully replicate the complexity of human neurodegenerative diseases, cognition, or aging. Improvements in selected animal tasks may not translate into meaningful clinical outcomes.
Another limitation concerns the distinction between restoring impaired performance and enhancing normal cognition. Even if a compound reliably improved memory-related behavior in an experimental model of impairment, this would not demonstrate that it improves learning or intelligence in healthy adults.
We therefore need to interpret the available findings according to what the experiments actually measured, rather than extending their conclusions beyond the evidence.
What About the Scientific Notices and Retracted Studies?
Scientific understanding develops through testing, replication, correction, and reassessment. Dihexa provides a clear example of why these processes matter, especially when experimental findings attract attention beyond the scientific community.
A 2013 publication by McCoy and colleagues investigated metabolically stabilized angiotensin IV analogs and reported findings relevant to cognition. In 2021, this publication received a formal Notice of Concern involving possible image manipulation. Importantly, a Notice of Concern is not the same as a retraction, but it signals that readers should interpret the affected research carefully.
A 2014 publication by Benoist and colleagues examined the proposed relationship between angiotensin IV-derived compounds and HGF/MET signaling. The paper was retracted in 2025 after an institutional investigation found falsified or fabricated experimental data in specific figures and related material. Other publications from the associated research program also received formal integrity actions.
These developments reduce confidence in some foundational findings, but they do not automatically settle every biological question surrounding Dihexa. Researchers can still investigate the compound using independent laboratories, transparent methods, and reproducible experimental designs.
From my perspective, the lesson is straightforward. We should remain open to scientific possibilities while ensuring that our conclusions reflect the quality of the available evidence. Curiosity and caution are complementary responsibilities in scientific inquiry.
Has Dihexa Been Tested in Human Clinical Trials?
This is one of the most important questions for anyone considering the practical significance of Dihexa research.
As of October 2026, I could not identify published human clinical trials or registered interventional studies of Dihexa itself demonstrating its effectiveness or safety. Dihexa is also not approved by the US Food and Drug Administration (FDA) as a medicine for any indication.
This means that essential clinical questions remain unanswered. We lack established human evidence on how Dihexa is absorbed and metabolized, how much reaches the brain, which molecular targets it affects at different exposures, and how its use might affect cognition over time.
We also lack validated human dosing protocols, adequate long-term safety data, and controlled clinical evidence showing improvements in memory, attention, or other meaningful cognitive outcomes.
It is important to distinguish Dihexa from other compounds developed within related research programs. For example, fosgonimeton has been investigated in human Alzheimer’s disease trials, but it is a chemically distinct compound. Results involving fosgonimeton cannot establish the effectiveness or safety of Dihexa.
The absence of human clinical evidence does not prove that Dihexa has no useful biological effects. It means that claims of clinical effectiveness remain unproven.
What Are the Potential Safety Concerns?
Safety is especially important when discussing experimental compounds intended to influence biological growth and signaling pathways. The nervous system depends on carefully regulated molecular communication, and interventions affecting one pathway may influence processes elsewhere in the body.
The proposed HGF/MET mechanism raises a theoretical concern because abnormal MET signaling has been implicated in certain cancers, including processes associated with tumor growth and invasion. This point does not mean that Dihexa has been demonstrated to cause cancer. Its proposed activity through this pathway remains uncertain, and adequate studies establishing its long-term human safety are unavailable.
Other questions concern possible effects on cardiovascular regulation, metabolism, interactions with medications, and prolonged changes in neuronal signaling. These possibilities require investigation rather than speculation. We should avoid presenting unknown risks as confirmed adverse effects, just as we should avoid presenting unverified benefits as established outcomes.
The availability of Dihexa through websites selling experimental compounds does not provide evidence of pharmaceutical quality, clinical effectiveness, or regulatory approval. Products described as research chemicals may not have undergone the manufacturing controls, purity verification, and safety assessments required for approved medicines.
For this reason, I would not recommend self-experimentation with Dihexa or interpreting informal dosing discussions as evidence-based medical guidance.
Why a Miracle Molecule Is an Attractive Idea
I understand why compounds associated with neuroplasticity generate excitement. Many people worry about memory decline, particularly as they grow older or watch loved ones experience neurological disease. The possibility of restoring lost connections or improving cognitive performance through a molecular intervention is understandably appealing.
This interest also has a deeper psychological root. We often prefer explanations that connect a complex problem to a single solution. If memory depends partly on synaptic connections, it may seem logical that increasing those connections would improve memory. Yet cognition involves far more than the number of synapses.
Attention, emotional regulation, sleep, metabolic health, vascular function, inflammation, and experience all influence how neural networks operate. A compound that modifies one molecular pathway cannot automatically coordinate these interacting systems.
Therefore, I prefer to view experimental compounds through a systems-based perspective. Molecular discoveries may eventually contribute to valuable therapies, but successful interventions must produce meaningful benefits within the broader biological and psychological conditions that support cognition.
The promise of Dihexa should therefore be understood as a research question, not a clinical achievement.
What Can We Learn About Cognitive Health Today?
One practical lesson from this research is that our brains retain meaningful adaptive capacity throughout life. Although neuroplasticity changes with aging, neural networks can continue modifying their connections in response to learning, activity, and experience.
We already have evidence supporting several behaviors that contribute to brain health. Regular physical activity, adequate sleep, meaningful cognitive engagement, social interaction, cardiovascular risk management, and appropriate treatment of medical conditions can support cognitive function and general well-being. These practices do not guarantee protection against dementia, but they have a stronger human evidence base than experimental Dihexa supplementation.
We should also distinguish cognitive health from cognitive enhancement. Preserving the capacity to learn, function independently, and maintain meaningful relationships may be more valuable than pursuing an uncertain increase in synaptic density.
For scientists and clinicians, the challenge is to identify biological interventions that provide benefits beyond existing approaches and demonstrate acceptable safety. For the public, the challenge is to interpret exciting discoveries without confusing experimental possibilities with available treatments.
Conclusions and Key Takeaways
Scientific Curiosity Without the Hype
Dihexa remains an interesting experimental peptidomimetic linked to research on synaptic plasticity and memory. Its development illustrates how medicinal chemistry can generate compounds designed to investigate biological signaling systems. Early experimental reports raised questions about its potential effects on neuronal connectivity, but evidence remains limited, and important foundational studies have faced scientific integrity actions.
The current scientific record does not establish that Dihexa improves human memory, prevents cognitive decline, treats Alzheimer’s disease, or safely enhances intelligence. No verified human clinical evidence supports these benefits, and the FDA has not approved the compound. Claims portraying it as a miracle molecule or describing extraordinary potency relative to BDNF should therefore be interpreted within their narrow experimental context.
I remain interested in the scientific questions surrounding Dihexa because understanding the molecular regulation of synaptic plasticity may eventually contribute to advances in neurological medicine. However, responsible interpretation requires independent replication, reliable mechanistic evidence, and carefully designed clinical studies. The history of biomedical research reminds us that many promising laboratory discoveries require years of investigation, and some never become effective treatments.
My central message is that the quality, regulation, and functional integration of neural connections matter more than simply increasing their number. Our brains are living systems whose cognitive capacities emerge from coordinated molecular, cellular, physiological, and psychological processes. We can remain enthusiastic about future discoveries while respecting the limitations of current evidence. That combination of scientific curiosity, intellectual humility, and appropriate caution serves researchers, clinicians, and the public alike.
Selected Research and Further Reading
McCoy, A. T., et al. (2013). Evaluation of Metabolically Stabilized Angiotensin IV Analogs as Procognitive/Antidementia Agents. Journal of Pharmacology and Experimental Therapeutics, 344, 141–154. DOI: 10.1124/jpet.112.199497. Publication carries a 2021 Notice of Concern.
Benoist, C. C., et al. (2014). The Procognitive and Synaptogenic Effects of Angiotensin IV–Derived Peptides Are Dependent on Activation of the Hepatocyte Growth Factor/c-Met System. Journal of Pharmacology and Experimental Therapeutics, 351, 390–402. DOI: 10.1124/jpet.114.218735. Retracted in 2025; included for historical context, not as valid mechanistic evidence.
Retraction Notice (2025). Journal of Pharmacology and Experimental Therapeutics, 392, 103567. DOI: 10.1016/j.jpet.2025.103567.
For readers interested in the broader context of brain connectivity, see my earlier essay: Synaptogenesis: How New Neural Connections Support Learning, Adaptation, and Cognitive Resilience.
Educational disclaimer: This article is intended to explain scientific research and does not provide medical advice or recommend the use of experimental compounds.
Thank you for reading my perspectives. I wish you a healthy and happy life.
[End of the Essay]
If you are a new reader, you may check out some of my thematic story collections on Medium:
Collection 1: Brain Health and Cognitive Function
Collection 2: Weight Loss / Muscle Gain
Collection 3: Nutrition and Customized Diets
Collection 4: Valuable Nutrients and Supplements
Collection 5: Fasting, Ketosis, Autophagy, Mitophagy
Collection 6: Ketosis and Ketogenic Lifestyle
Collection 7: Major Health Conditions
Collection 8: Clinical Trials I Reviewed
Collection 9: Importance of Sleep for Health
Collection 10: Aging and Longevity
Collection 11: Writing, Content Development & Marketing Strategy Guides
Collection 12: My Most Loved Stories By Avid Readers
You can check out my FEATURED series of 70+ books on Amazon marketplaces:
I also added my catalog of digital and audiobooks from Google to a collection that can be accessed easily:
Digital and Audiobooks by Dr Mehmet Yildiz on Google Play — The Digitalmehmet Content Ecosystem
50+ Digital and Audiobooks links by Dr Mehmet Yildiz on Google Play and Google Books for easy access. Other platform…digitalmehmet.com
If you are a writer, you are welcome to join my publications by sending a request via this link. I support 43K writers who contribute to my publications on this platform. Check out the recent update for the writers of my publications.
You can contact me via my website. If you are a new writer, check out my writing list to find some helpful stories for your education. You can also join my author platform as a guest blogger.
I interviewed several new professionals and thought leaders. You can find them linked at the end of the latest one.
I invite you to subscribe to my publications on Substack, where I offer experience-based and original content on health, content strategy, book authoring, and technology topics you can’t find online to inform and inspire my readers.
Healthspan Mastery (NEW)
Get an email whenever Dr. Mehmet Yildiz publishes. He is a top writer and editor on Medium.
dr-mehmet-yildiz.medium.com
Check out Free Blog Posts by Digitalmehmet Contributors. Here is the link to my FREE personal blogs. Now you can read our blog posts via a Flipboard Magazine for convenience.
I invite you to explore some of my books on my discount bookstore including:Train Your Brain for a Healthier and Happier Life, Cortisol Clarity, Ketosis + BDNF: The Healing Molecules That Saved My Life, The Science & Wisdom of Graceful Aging, The LIFE Matrix Keeps the Score, How I Accelerated My Learning Effortlessly for a Happier Life, Neurocomputing and Neural Architectures, Substack Mastery Version 2, The Zen of Book Authoring, Monetize Your Passion with WooCommerce, Agile Business Architecture for Digital Transformation V2, Agile Business Architecture for Digital Transformation (Audiobook), A Powerful Toolkit for Substack Newsletter Mastery, Smart and Ethical SEO, Modern Affiliate Marketing for Writers, 4 Pillars of Enterprise Architecture, and Smart Email Marketing Content Integration, The Mysterious Leadership Mind of Robert F.Kennedy Jr., Cognitive Computing Reimagined.
Share links to your newsletters here and share links to your stories here
I invite book authors to share links to their books via this resource.
Leave a Reply